MaxCyte, Inc. Notice of AGM and Annual Report (4680M)
30 April 2018 - 4:02PM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 4680M
MaxCyte, Inc.
30 April 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of AGM and 2017 Annual Report and Accounts
Gaithersburg, Maryland - 30 April 2018: MaxCyte (LSE: MXCT,
MXCR), the global cell-based medicines and life sciences company,
gives notice that copies of the 2017 Annual Report and Accounts and
the Notice of Annual General Meeting have been sent to
Stockholders. These documents are available on the "Investors"
section of the Company's website at www.maxcyte.com.
Further copies of the Annual Report will be available from the
Company Secretary, MaxCyte, Inc., 22 Firstfield Road, Suite 110,
Gaithersburg, MD 20878, USA.
MaxCyte also announces that its Annual General Meeting of
Stockholders is planned to be held on 31 October 2018. Formal
notice and resolutions, along with the Annual Meeting Proxy Card,
will be circulated on or about 10 September 2018 to Stockholders of
record on or about that date.
###
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley
Ryan McCarthy +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Suki Virji
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology to help
patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA(TM) therapies for its
own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform
for autologous cell therapy. In addition, through its core
business, the Company leverages its Flow Electroporation(R)
Technology to enable its partners across the biopharmaceutical
industry to advance the development of innovative medicines,
particularly in cell therapy, including gene editing and
immuno-oncology. The Company has placed its cutting-edge flow
electroporation instruments worldwide, including with nine of the
top ten global biopharmaceutical companies, and has more than 50
partnered programme licences in cell therapy including more than 20
licensed for clinical use. With its robust delivery technology,
MaxCyte helps its partners to unlock the full potential of their
products.
For more information, visit www.maxcyte.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOALLFVRSTIDFIT
(END) Dow Jones Newswires
April 30, 2018 02:02 ET (06:02 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024